PROSTAMAX (Supplier Trade Name)
Supplier trade-name product · API to be confirmed
Overview
PROSTAMAX is a supplier trade-name product, typically marketed in the upstream supplier-catalog space as a prostate-targeting short-peptide preparation. The product is most commonly seen in Russian and Eastern European peptide-bioregulator catalogs, where trade-name preparations targeting specific organ systems are an established commercial pattern that overlaps with the Khavinson bioregulator framework. The actual composition is proprietary to the upstream manufacturer and must be confirmed against the batch-specific COA before any order placement. Lyochem lists PROSTAMAX to support distributor-partner workflows that reference upstream price tables. Direct end-buyers should consider the named-molecule equivalents in the Khavinson family (when a prostate-tissue Khavinson peptide is the underlying material) or engage the regulatory team for explicit composition disclosure before ordering. The 20 mg standard vial matches the format pattern of the broader Khavinson catalog.
Who buys this, and why
Khavinson short bioregulators — Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen — ship to research labs replicating Russian-school protocols or running comparative tissue-specific peptide-bioregulator studies. The published literature base for this class is concentrated in Russian-language sources; buyers should expect to consult that literature directly for protocol selection. Analytical-packet expectations are the same as any other lyophilised research peptide.
Primary buyer fit: regional research-supplier partners and university-block resellers.
Specifications
- CAS
- (supplier code, confirm via COA)
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 20 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Source-literature pointer (Russian-language references on request)
- Stability at −20 °C across 12 months
- Sequence ladder available on request
Regulatory note
Supplier trade-name product without publicly disclosed API identity; composition must be confirmed via batch-specific COA before any downstream regulatory or research use.
Frequently asked questions
Is PROSTAMAX related to the Khavinson framework, given the tissue-specific naming?▾
PROSTAMAX is positioned within the broader Russian-school short-peptide bioregulator framework that overlaps with the Khavinson research lineage, both share the design pattern of short tissue-specific peptide preparations marketed for the corresponding tissue indication. The exact composition of PROSTAMAX is proprietary to the upstream manufacturer and may or may not be a single defined peptide (some PROSTAMAX preparations are multi-peptide extracts similar to Cerebrolysin or Cortexin). Buyers conducting research with PROSTAMAX should request explicit composition disclosure from the regulatory team and reference the original Russian-language publications if replicating published protocols, rather than assume mechanistic equivalence to named single-peptide Khavinson products.
What's the research context for prostate-targeting short peptides in the Russian-school framework?▾
Russian-school publications on prostate-targeting short peptides focus on age-related benign prostatic hyperplasia (BPH) and prostate-tissue gene-expression modulation in aged-rodent models. The mechanism hypothesis within the Khavinson framework is that short tissue-specific peptides isolated from young-animal prostate tissue can act as endogenous-mimetic bioregulators of prostate gene expression, supporting tissue homeostasis and counteracting age-related dysregulation. Reported readouts in published animal studies include modulation of prostate-tissue proliferation markers and inflammation markers. As with the broader Khavinson framework, the evidence base is concentrated in Russian-language journals; PROSTAMAX should be treated as an investigational research tool rather than a clinically-validated prostate therapeutic.
What documentation can Lyochem provide for PROSTAMAX clinical use considerations?▾
Because PROSTAMAX's exact composition is proprietary to the upstream manufacturer and the molecule is not approved as a finished drug in any major regulatory framework, Lyochem cannot provide standard pharmaceutical-product documentation (no SPC, no monograph, no approved dosing). What we do provide on every shipment: (1) batch-specific COA covering the verified composition of the released material, (2) HPLC chromatogram and mass-spec data for the dominant species in the preparation, (3) sterility and microbial-limits testing for injectable-route applications, and (4) regulatory advisory on the destination market's current treatment of similar Russian-origin peptide preparations. Clinical use is the buyer's responsibility under their local regulatory framework.